Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Back to dashboard
Company Information
About this company
Key people
Alexis A. Borisy
Independent Chairman of the Board
Sanjiv K. Patel
President, Chief Executive Officer, Director
Thomas Catinazzo
Chief Financial Officer
Donald A. Bergstrom
President - Research and Development
Peter Rahmer
Chief Corporate Development Officer
Lonnel Coats
Independent Director
Habib Joseph Dable
Independent Director
Linda A. Hill
Independent Director
Douglas S. Ingram
Independent Director
Click to see more
Key facts
- Shares in issue219.14m
- EPICRLAY
- ISINUS75943R1023
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.57bn
- Employees202
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.